# Archer-Daniels-Midland Company (ADM) — Financial Analysis

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-27  
**Tier:** Free primer (step 2 of 19)  
**Sibling pages:** /stocks/ADM/thesis · /stocks/ADM/memo

## Financial Snapshot

---
title: "Step 04 — Financial Quality & Adversarial Sweep"
ticker: ADM
company: Archer-Daniels-Midland Company
source: coverage-next-full
created: 2026-05-27
---

### Step 04 — Financial Quality: Archer-Daniels-Midland Company (ADM)

#### 1. Statement Quality Assessment

##### Income Statement Quality
ADM's income statements have been materially affected by the 2024 accounting restatements. Key quality considerations:

**Restatement Impact [S5]:**
- In January 2024, ADM disclosed a voluntary SEC inquiry into intersegment accounting practices, specifically how the Nutrition segment recorded transactions with other business units
- Multiple financial restatements were filed in 2024 (March and November), restating years of prior financial reports
- The investigation alleges improper revenue recognition through inflated intersegment sales — estimated at ~$228M over multiple years per the Athena Research short report [S5]
- CFO Vikram Luthar was placed on administrative leave (Jan 2024) and resigned (Sep 2024); Monish Patolawala appointed as new CFO

**Adjusted EPS vs. GAAP EPS:** ADM reports "adjusted EPS" excluding restructuring, impairments, and legal charges. For FY2025, GAAP EPS was $2.23 vs. adjusted guidance range of $4.00-$4.75 — a wide gap that reflects the severity of restatement/legal charges. The adjusted metric is management's preferred communication vehicle but now carries credibility questions [J].

**SBC and Non-Cash Items:** Stock-based compensation is ~$100-150M annually (estimated). Not a primary earnings quality concern at this scale [J].

##### Balance Sheet Quality
**Shareholders' Equity Anomaly [S1]:** StockAnalysis data shows a dramatic jump in shareholders' equity from $320M (FY2023) to $22.4B (FY2024). This appears to reflect restatement-related adjustments that corrected accumulated equity. The post-restatement balance sheet ($22.4B equity, FY2024) is more representative of true book value. Working capital is substantial (~$10-15B) due to commodity trading inventories and receivables.

**Goodwill Impairment Watch:** ADM carried $4.5-4.8B in goodwill (FY2024-25), primarily from the Wild Flavors (2014, ~$3B) and Neovia (2019) acquisitions. Given the Nutrition segment's underperformance, goodwill impairment risk exists but has not been triggered as of FY2025 [J].

##### Cash Flow Quality
**FCF Recovery: Positive Signal [S1]:** Free cash flow jumped to $4.2B in FY2025 vs. $1.2B in FY2024. This was driven partly by working capital release (inventory reduction as commodity prices fell) — a one-time benefit. Normalized FCF at mid-cycle is likely $2-3B, still healthy relative to dividends (~$1B) [J].

#### 2. Key Financial Ratios (FY2025)

| Metric | Value | Commentary |
|--------|-------|-----------|
| Gross Margin | 6.3% | Below 5-year average; commodity cycle trough |
| Operating Margin | 1.4% | At trough; high fixed cost absorption |
| Net Margin | 1.3% | Low; elevated interest expense on ~$9.8B debt |
| FCF Margin | 5.2% | Strong; working capital release tailwind |
| Return on Equity | ~4.7% (GAAP) | Depressed; restated equity base |
| Return on Assets | ~2.1% | Low; asset-intensive business |
| Current Ratio | ~1.5x (est.) | Adequate; large working capital needs |
| Net Debt/EBITDA | ~3.8x | Elevated; leverage near management's tolerance |
| Interest Coverage | ~3-4x (EBIT/Interest) | Manageable but not comfortable |

#### 3. Adversarial Research Sweep

##### A. Accounting Investigation (ACTIVE — HIGH RISK)

**What happened:** ADM disclosed in January 2024 that it received a voluntary SEC document request related to intersegment accounting practices. The investigation centers on how the Nutrition segment recorded sales to other ADM business units — specifically, whether revenues between segments were inflated to make the Nutrition segment appear more profitable than it was [S5].

**DOJ Investigation:** The US Department of Justice launched a parallel investigation in March 2024, issuing subpoenas to current and former ADM employees [S5].

**Financial Restatements:** ADM restated multiple years of financial results. The restated amounts reduced historical Nutrition segment profitability. Per the Athena Research "ShortSight Brief," approximately $228M in accounting adjustments were identified across multiple periods [S5].

**Securities Fraud Class Action:** A class action lawsuit was filed in the Northern District of Illinois. In March 2025, a federal judge denied ADM's motions to dismiss the case, ruling that evidence was sufficient for the lawsuit to continue [S5]. Named defendants include CEO Juan Luciano, former CFO Vikram Luthar, former CFO Ray G. Young, and former Nutrition president Vince Macciocchi.

**Status as of May 2026:** DOJ investigation ongoing; class action proceeding. No settlement announced.

**Risk Assessment [J]:** The core risk is whether this represents isolated bad actors in the Nutrition segment or a broader culture of financial manipulation. Management's response (cooperating with SEC, terminating CFO, hiring external legal counsel) suggests an attempt at remediation, but the ongoing DOJ investigation and court-proceeding class action represent material unresolved tail risk. Settlement exposure is uncertain but could be $200-500M+.

##### B. Shareholder Activism (ACTIVE — MEDIUM RISK)

In December 2024, shareholder Hartwig Fuchs publicly called for CEO Juan Luciano's resignation, citing the accounting scandal and a ~50% stock price decline from peak [S5]. While this has not escalated to a formal proxy contest (as of May 2026), it signals investor frustration and potential for further governance pressure.

##### C. Short Seller Activity

Athena Research published a "ShortSight Brief" on ADM (referenced in news searches), estimating $228M in accounting adjustments and framing the situation as "the $228M Accounting Magician that DOJ is Now Investigating" [S5]. This short thesis predated the formal DOJ investigation announcement. The stock has declined ~40% from its 2023 peak, suggesting the market has partially priced in these risks.

##### D. Competitive Threat (Bunge-Viterra Merger)

The 2024-25 merger of Bunge Limited and Viterra created a larger, better-capitalized competitor in global oilseed processing and Americas grain origination [S5]. This is a structural competitive headwind, not a fraud risk, but it puts pressure on ADM's AS&O margins going forward.

##### E. Trade Policy Risk (US-China Tensions)

US-China trade tensions (tariffs, retaliatory measures) can disrupt traditional soybean export flows. In 2018, China imposed retaliatory tariffs on US soybeans, which materially hurt US origination premiums. A recurrence of aggressive trade restrictions represents a significant macro risk to ADM's AS&O origination business [S5][J].

#### 4. Overall Financial Quality Assessment

**Summary [J]:** ADM's financial quality is BELOW AVERAGE for a large-cap US company due to: (1) ongoing accounting investigation with unresolved DOJ exposure, (2) track record of restatements, (3) ROIC below WACC, and (4) elevated leverage at cyclical trough earnings. These are partly offset by: strong FCF generation, dividend sustainability, and a commodity processor business model that is inherently thin-margin but not manipulable at scale (physical grain volumes are independently verifiable). The accounting issues appear isolated to the Nutrition segment's intersegment accounting rather than a systemic revenue fabrication scheme.

#### 5. Source Index

- [S1] StockAnalysis.com — Financial ratios, equity data; retrieved 2026-05-27
- [S2] ADM IR — Segment detail; retrieved 2026-05-27
- [S5] Web search — DOJ/SEC investigation, class action lawsuit, Athena Research, Fuchs shareholder letter; retrieved 2026-05-27
- [J] Analyst judgment

## Deeper Financial Analysis

The fundamental tier ($1.00) adds 8 dimensions not included here:

- Revenue Breakdown — segment revenue, geographic mix, product-line margins
- Financial Trends — QoQ momentum, leading indicators, inflection points
- Balance Sheet — debt structure, dilution risk, working capital dynamics
- Capital Allocation — ROIC, buyback cadence, reinvestment efficiency
- Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights
- Competitive Positioning — market share, pricing power, peer benchmarks
- Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop

**API endpoint:** GET /api/v1/research/ADM/fundamental

## Navigation

- Overview: /stocks/ADM
- Financials (this page): /stocks/ADM/financials
- Thesis: /stocks/ADM/thesis
- Investment Memo: /stocks/ADM/memo
- Coverage universe: /stocks